A structured narrative synthesis of STAT3 regulation in liver fibrosis is provided to dissect the current status and challenges of targeted therapeutic strategies, and discuss how context-matched STAT3 modulation may inform future anti-fibrotic strategies.
Abstract
Liver fibrosis is a central pathological process driving the progression of chronic liver disease to cirrhosis and involves complex signaling networks across multiple cell types. Signal transducer and activator of transcription 3 (STAT3) serves as a signaling hub that integrates inflammatory, metabolic, and fibrogenic signals and exerts pleiotropic regulatory functions in liver fibrosis. STAT3 structure and subcellular localization provide the scaffold for signal encoding, whereas post-translational modifications (PTMs) alter STAT3 stability, dimerization, localization, transcriptional activity, and protein interactions. These regulatory states are further translated through direct transcriptional control, epigenetic mechanisms, non-coding RNA networks, signaling crosstalk, metabolic reprogramming, and oxidative stress into cell-specific phenotypes within the fibrotic microenvironment. Current evidence most consistently supports a pro-fibrotic role for STAT3 activation in HSC-centered fibrogenic programs, whereas several PTM-dependent, metabolic, and cell-protective mechanisms remain context-restricted or incompletely validated. Herein, we provide a structured narrative synthesis of STAT3 regulation in liver fibrosis, dissect the current status and challenges of targeted therapeutic strategies, and discuss how context-matched STAT3 modulation may inform future anti-fibrotic strategies.
Current advances in understanding transcriptional regulatory networks governing fibroblast activation were summarized, with a primary focus on HSCs while highlighting shared mechanisms across multiple fibrotic organs.
Denita Charoenthanakitkul, Chaiyaboot Ariyachet· International Journal of Mol...· 0 citations
This review summarizes the principal epigenetic changes involved in HSC activation, initiation/progression of liver fibrosis, and discusses recent interventions designed to modulate these epigenetic changes.
M. J. Tavaf, M. E. Varkiani, Saeid Abroun et al.· Portal Hypertension & Ci...· 0 citations
An in-depth study of the regulatory network of chromatin accessibility may provide new perspectives on the pathogenesis of liver fibrosis and lay a theoretical foundation for the development of novel precision-targeted drugs.
Xue Dong, Ming-Hui Li, Zheng-Lin Qiao et al.· European Journal of Pharmaco...· 0 citations
While p38 MAPK represents a promising therapeutic target for liver fibrosis, future research should focus on developing isoform-specific inhibitors, understanding context-dependent signaling outcomes, and designing combination therapies to enhance efficacy and minimize off-target effects.
Xueqin Yang, Hua-Rong Li, Hao-Sen Ye et al.· International Journal of Mol...· 0 citations
The molecular regulatory network of HIF-1 in liver fibrosis is reviewed to provide theoretical support and identify future research directions for targeted therapy of liver fibrosis, thereby facilitating the clinical translation of relevant treatment approaches.
Cai-Yun Zhou, Li Wang· Journal of Applied Genetics· 0 citations
A comprehensive framework of kinase-microRNA (miRNA) crosstalk as an emerging regulatory axis in cardiometabolic disease is presented, establishing kinase-miRNA crosstalk as a promising mechanistic framework and therapeutic target for precision intervention in heart failure, atherosclerosis, diabetic cardiomyopathy, an...
Firdos Ahmad, Asima Karim, M. Kannan et al.· Journal of molecular medicin...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.